Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Antimicrob Agents Chemother. 2012 Nov;56(11):5575-80. doi: 10.1128/AAC.01136-12. Epub 2012 Aug 13.
There has been a significant increase in the prevalence of Enterobacteriaceae that produce CTX-M-type extended-spectrum β-lactamases. The objective of this study was to evaluate risk factors for infection or colonization with CTX-M-positive Escherichia coli. A case-control study was conducted within a university system from 1 January 2007 to 31 December 2008. All patients with clinical cultures with E. coli demonstrating resistance to extended-spectrum cephalosporins were included. Case patients were designated as those with cultures positive for CTX-M-positive E. coli, and control patients were designated as those with non-CTX-M-producing E. coli. Multivariable logistic regression analyses were performed to evaluate risk factors for CTX-M-positive isolates. A total of 83 (56.8%) of a total of 146 patients had cultures with CTX-M-positive E. coli. On multivariable analyses, there was a significant association between infection or colonization with CTX-M-type β-lactamase-positive E. coli and receipt of piperacillin-tazobactam in the 30 days prior to the culture date (odds ratio [OR], 7.36; 95% confidence interval [CI], 1.61 to 33.8; P = 0.01) and a urinary culture source (OR, 0.36; 95% CI, 0.17 to 0.77; P = 0.008). The rates of resistance to fluoroquinolones were significantly higher in isolates from case patients than in isolates from control patients (90.4 and 50.8%, respectively; P < 0.001). We found that nonurinary sources of clinical cultures and the recent use of piperacillin-tazobactam conferred an increased risk of colonization or infection with CTX-M-positive E. coli. Future studies will need to focus on outcomes associated with infections due to CTX-M-positive E. coli, as well as infection control strategies to limit the spread of these increasingly common organisms.
产 CTX-M 型超广谱β-内酰胺酶的肠杆菌科的流行率显著增加。本研究旨在评估感染或定植产 CTX-M 型大肠埃希菌的危险因素。这是一项在 2007 年 1 月 1 日至 2008 年 12 月 31 日期间在一个大学系统内进行的病例对照研究。所有具有对头孢菌素类药物表现出耐药性的大肠埃希菌临床培养物的患者均被纳入研究。病例组患者被指定为 CTX-M 阳性大肠埃希菌培养阳性的患者,对照组患者被指定为非产 CTX-M 大肠埃希菌的患者。采用多变量逻辑回归分析评估 CTX-M 阳性分离株的危险因素。在总共 146 例患者中,共有 83 例(56.8%)的培养物中发现了产 CTX-M 型β-内酰胺酶的大肠埃希菌。多变量分析显示,在培养日期前 30 天内接受哌拉西林-他唑巴坦治疗(比值比 [OR],7.36;95%置信区间 [CI],1.61 至 33.8;P = 0.01)和尿培养物来源(OR,0.36;95%CI,0.17 至 0.77;P = 0.008)与感染或定植产 CTX-M 型β-内酰胺酶的大肠埃希菌显著相关。与对照组患者相比,病例组患者的分离株对氟喹诺酮类药物的耐药率明显更高(分别为 90.4%和 50.8%;P < 0.001)。我们发现,非尿源临床培养物和近期使用哌拉西林-他唑巴坦会增加感染或定植产 CTX-M 型大肠埃希菌的风险。未来的研究将需要重点关注由产 CTX-M 型大肠埃希菌引起的感染相关结局,以及感染控制策略,以限制这些日益常见的病原体的传播。